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REVIEW
Abstract: Diabetes-associated vascular complications are collectively the major clinical
problems facing patients with diabetes and lead to the considerably higher mortality rate than
that of the general population. People with diabetes have a much higher incidence of coronary
artery disease as well as peripheral vascular diseases in part because of accelerated
atherogenesis. Despite the introduction of new therapies, it has not been possible to effectively
reduce the high cardiovascular morbidity and mortality associated with diabetes. Of additional
concern is the recognition by the World Health Organization that we are facing a global
epidemic of type 2 diabetes. Endothelial dysfunction is an early indicator of cardiovascular
disease, including that seen in type 2 diabetes. A healthy endothelium, as defined in terms of
the vasodilator/blood flow response to an endothelium-dependent vasodilator, is an important
indicator of cardiovascular health and, therefore, a goal for corrective interventions. In this
review we explore the cellular basis for endothelial dysfunction in an attempt to identify
appropriate new targets and strategies for the treatment of diabetes. In addition, we consider
the question of biomarkers for vascular disease and evaluate their usefulness for the early
detection of and their role as contributors to vascular dysfunction.
Keywords: endothelium, diabetes, nitric oxide (NO), C-reactive protein (CRP), asymmetric
dimethylarginine (ADMA), endothelial progenitor cells (EPCs)
Diabetes – the problem
“Diabetes is a growing and massive silent epidemic that has the potential to cripple
health services in all parts of the world”, quote from Dr Robert Beaglehole, Director
Chronic Diseases and Health Promotion, speaking at the launch of Diabetes Action
Now, 5 May, 2004. Diabetes Action Now is a joint program of the World Health
Organization and the International Diabetes Federation; further information can be
found on the World Health Organization website.
The incidence of type 2 diabetes (characterized initially by insulin resistance,
whereas type 1 is characterized by insulin deficiency) has already reached epidemic
proportions. To date, epidemics have been associated with communicable diseases;
however, type 2 diabetes is the only non-infectious condition that has been
classified as an epidemic. According to the World Health Organization, there are
some 150 million diagnosed cases of type 2 diabetes in the world, and current estimates
predict that this will increase to 300 million by 2025. An unofficial estimate, given
the suspected high number of undiagnosed cases, boosts the current number of people
with diabetes to 1.2 billion. Regardless of the accuracy of these estimates, there are
severe global and societal implications resulting from this emerging epidemic in
diabetes (Zimmet et al 2001). The increase in the incidence of type 2 diabetes is
mainly the result of genetic predisposition and a higher standard of living that has
Hong Ding
Chris R Triggle
School of Medical Sciences, RMIT
University, Bundoora West Campus,
Bundoora, VIC, Australia
Correspondence: Chris R Triggle
School of Medical Sciences, RMIT
University, Bundoora West Campus,
Plenty Road, Bundoora, VIC 3083,
Australia
Tel +61 3 9925 6537
Fax +61 3 9925 6555
Email chris.triggle@rmit.edu.au
Endothelial cell dysfunction and the vascular
complications associated with type 2 diabetes:
assessing the health of the endotheliumVascular Health and Risk Management 2005:1(1) 56
Ding and Triggle
changed eating habits and led to a more sedentary lifestyle.
The link between genetically determined susceptibility and
“lifestyle” is particularly intriguing. The incidence of type
2 diabetes in North Americans and individuals of European
origin has risen from 2% in 1981 to 8% in 2002; the increase
in “westernized” indigenous people is even more dramatic,
from essentially 0% to as high as 50% in some societies
(Diamond 2003). This increase in the incidence of type 2
diabetes has already placed a huge burden on healthcare,
and the early detection, treatment, and preferably prevention
of type 2 diabetes are significant challenges for this century.
With an alarming increase in the number of overweight
adults and children in the Western world, the need for better
treatment regimens and early diagnosis of vascular disease
has never been greater.
Another concern for the global impact of type 2 diabetes
is an apparent association between the use of certain drugs
for the treatment of AIDS and an increase in the incidence
of diabetes in people with AIDS. Concurrent with the
improvement in life expectancy and quality of life of AIDS
patients by the increased availability of HIV-1 protease
inhibitors and highly active antiretroviral therapy (HAART)
is evidence that long-term HAART leads to insulin
resistance, impaired glucose tolerance, and also dyslipidemia
and thus an increase in the prevalence of diabetes and
cardiovascular disease in people with AIDS (Mondal et al
2001; Tershakovec et al 2004). It was reported in the 2004
Report on the Global AIDS Epidemic (UNAIDS 2004) that
there are approximately 38 (range 34.6–42.3) million people
worldwide living with HIV and this number is increasing
by about 3 million a year – an additional frightening statistic
to the worldwide problem of diabetes.
Diabetes – a vascular disease
Diabetes-associated vascular complications are a major
clinical problem, and diabetic patients have a mortality rate
3–4 times that of the general population (Haffner et al 1998).
Diabetic patients have a 2- to 4-fold increase in the incidence
of coronary artery disease (CAD) and 10-fold increase in
peripheral vascular diseases (Laakso 1999), in part because
of accelerated atherogenesis.
Cardiovascular disease and the
endothelium
Communication between endothelial and vascular smooth
muscle cells and vice versa plays an important role in the
regulation of vascular tone. Impaired endothelial function,
characterized by nitric oxide (NO) scavenging due to
increased superoxide (•O2
–) production, is a hallmark of
vascular disease states. Endothelial dysfunction can result
in a number of pathophysiological complications such as
enhanced inflammatory responses, ie, increased leukocyte-
endothelial cell adhesions (Pieper 1999), possibly due to
the increased expression of adhesion molecules (Li and
Forstermann 2000), enhanced activation of platelets and
clotting factors resulting in a procoagulant state, and
ultimately structural changes resulting from defective
modulation of vascular growth and remodeling by the
endothelium (for review see McLeod et al 1995). Up to 75%
of patients with diabetes die from vascular disease and
dysfunction of the endothelium. Endothelial dysfunction
plays an early (possibly preceding frank symptoms of
diabetes itself) and prominent role in this process (Andrews
et al 1987; Cohen et al 1988). In addition, vascular
dysfunction can continue to progress after a hyperglycemic
insult despite the subsequent maintenance of normal blood
glucose levels (so-called hyperglycemic memory)
(Engerman and Kern 1987; Fioretto et al 1998).
Endothelial dysfunction can be defined as a reduced
endothelium-dependent vasodilator response to
acetylcholine1 and, although the endothelium has many
additional functions beyond the control of vascular tone,
this reduced response to acetylcholine serves as an important
indicator of vascular dysfunction (De Vriese et al 2000;
Pannirselvam et al 2003; Triggle et al 2003; Andrews et al
in press).
Endothelial function can be readily measured using
isolated blood vessels and studying the ability of
endothelium-dependent vasodilators, such as acetylcholine,
to relax vessels with pre-existing tone either under “organ
bath” (for macrovessels) or “wire myograph” (for
microvessels) conditions (Mulvany and Halpern 1977).
Endothelial function can also be assessed in microvessels,
under pressurized conditions wherein either the effects of
endothelium-dependent vasodilator-mediated or flow-
mediated dilations can be assessed (for review see Davis
and Hill 1999). Endothelium function can be assessed using
in vitro techniques with isolated vessels from humans;
however, the data generated, by virtue of the limitations in
the sources of the tissues, often reflect function in diseased
vessels only, and a reference to a normal non-diseased
control is usually absent. Thus in humans both invasive and
non-invasive in vivo techniques are employed and include
direct intracoronary measurements, positron emission
tomography, impedance plethysmography, brachialVascular Health and Risk Management 2005:1(1) 57
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ultrasound, and, for venous studies, dorsal hand vein
compliance. The utility of these techniques has been
reviewed by Anderson (1999), with intracoronary measures
providing the gold standard. In humans the status of the
endothelium (Anderson 1999; Verma and Anderson 2002;
Verma, Szmitko, and Anderson 2004) is an important
surrogate marker of atherosclerosis activity. In addition,
attenuation of endothelium-dependent vasodilation is
associated with an increased risk of cardiovascular
complications during long-term follow-up (Halcox et al
2002). It is therefore not surprising that endothelium
dysfunction is seen as a key risk factor and the endothelium
as a target for correctional intervention (De Vriese et al 2000;
Pannirselvam et al 2003; Triggle et al 2003; Aird 2004;
Andrews et al in press), although outcomes may be
complicated by the increasing evidence that the endothelium
represents a heterogeneous population of cells with,
probably, considerable vessel specialization (Andrews et al
in press).
Several clinical studies have specifically addressed the
question as to whether improving glycemic control in
diabetes also improves endothelial function, and the results
and significance of some of these studies are discussed
below.
Mather et al (2001) measured blood flow responses to
intra-arterial administration of the endothelium-dependent
(acetylcholine) and endothelium-independent (sodium
nitroprusside) agonists as well as nitrate-independent
(verapamil) vasodilators using forearm plethysmography.
Data from their study provided the first in vivo evidence
that, in type 2 diabetic patients, metformin therapy for
12 weeks significantly improved acetylcholine-stimulated,
endothelium-dependent vasodilation compared with
placebo. The improvement in endothelial function probably
reflects the beneficial influence of metformin on insulin
resistance and glucose-lowering and antioxidant effects, and
possibly favorable effects on lipids and free fatty acids as
well as direct vasodilating actions. Peroxisome proliferator-
activated receptor-gamma (PPARγ) agonists, notably the
thiazolidinediones (glitazones), such as rosiglitazone, are
being used as insulin-sensitizers in the treatment of type 2
diabetes and, in some studies, endothelial function has been
assessed. Thus, Caballero et al (2003) used high-resolution
ultrasound images to determine the effects of troglitazone
treatment on endothelium-dependent flow-mediated
dilation and endothelium-independent nitroglycerin-induced
dilation in the brachial artery, as well as laser Doppler
perfusion imaging to measure acetylcholine- and sodium
nitroprusside-mediated vasodilation in the forearm skin.
Their results indicate that 12 weeks of troglitazone treatment
improved endothelial function in the macrocirculation of
patients with recently diagnosed type 2 diabetes, and
improvement was strongly associated with the improvement
of fasting plasma insulin. Sidhu et al (2004) studied another
glitazone, rosiglitazone, and demonstrated reduced markers
of inflammation and endothelial activation. Despite
rosiglitazone treatment significantly reducing C-reactive
protein (CRP; the significance of which is discussed later
in this review), the circulating endothelial cell marker von
Willebrand factor, insulin resistance index, and mean low-
density lipoprotein (LDL), compared with placebo, there
was no improvement in flow-mediated dilation in diabetic
patients (Sidhu et al 2004). We await additional results from
other clinical trials that are investigating the effects of
glitazones on the endothelium and cardiovascular morbidity
(eg, the GATE – Glitazones And The Endothelium – Study).
Exercise alone can improve endothelial function in
patients with stable CAD. A study by Hambrecht et al (2003)
demonstrated that exercise training in stable CAD improved
agonist-mediated, acetylcholine-mediated, endothelium-
dependent vasodilation as assessed invasively in the left
internal mammary artery before and after 4 weeks of
exercise training on bicycle and row ergometers. The change
in acetylcholine-induced vasodilation was linked to a
shear stress-induced/Akt (protein kinase B)-dependent
phosphorylation of endothelial nitric oxide synthase (eNOS)
on Ser1177; shear stress activation of eNOS had been
previously reported by Dimmeler et al (1999).
Yeh (2004) credits Dr William Osler with stating in his
Principles and Practice of Medicine: “Longevity is a
vascular question. A man is only as old as his arteries”.
Today we might change that to “a man is only as old as his
endothelium”. We therefore need to investigate and assess
techniques whereby the health of the endothelium can be
accurately monitored.
Endothelium-derived vasoactive
factors
Vascular tone is intricately regulated by a number of
vasorelaxant and contractile factors synthesized and released
from endothelial cells: vasodilators (NO, prostacyclin,
endothelium-derived hyperpolarizing factor, bradykinin,
adrenomedullin, C-natriuretic peptide) and vasoconstrictors
(endothelin-1, angiotensin-II, thromboxane A2, prosta-
glandins, hydrogen peroxide (H2O2), reactive oxygenVascular Health and Risk Management 2005:1(1) 58
Ding and Triggle
species (ROS)) (McGuire et al 2001; Triggle et al 2003).
The L-arginine-NO pathway is, however, thought to be the
most important vasodilator source. In addition to its function
as a vasodilator, NO, released from endothelial cells, reduces
vascular permeability, is a potent inhibitor of platelet
aggregation and adhesion to the vascular wall, controls the
expression of proteins involved in atheroma formation, and
decreases the expression of the chemoattractant protein
monocyte chemoattractant protein (commonly known
as MCP-1) and of surface adhesion molecules such as
CD11/CD18, P-selectin, vascular cell adhesion molecule-1
(VCAM-1), and intercellular adhesion molecule (ICAM-1).
In addition, NO decreases oxidation of LDL and inhibits
proliferation of vascular smooth muscle cells (Li and
Forstermann 2000), producing antiatherogenic effects.
NO is synthesized by a family of oxidoreductases, called
NO synthases (NOS), that bear close sequence homology
to cytochrome P450 (CYP) enzymes. Three isoforms are
known to exist: endothelial (eNOS), inducible (iNOS), and
neuronal (nNOS). In the endothelium eNOS is activated by
a number of agonists acting on G protein-coupled receptors
and by physical stimuli such as shear stress and changes in
oxygen levels that lead to the activation of stretch-operated
nonselective cation channels. NO is cleaved from L-arginine
and this process requires a number of cofactors:
nicotinamide adenine dinucleotide phosphate (NADPH),
flavin adenine dinucleotide (FAD), heme, flavin adenine
mononucleotide (FMN), calmodulin, and tetrahydro-
biopterin (BH4).
Of relevance to diabetes is the link between the
availability of BH4 and cardiovascular disease (Alp and
Channon 2004). Numerous studies, in both humans and
animals, have demonstrated the beneficial effects of BH4
on endothelial function. The heterogeneity of the human
populations (as well as the animal models) wherein
beneficial effects of BH4 have been reported indicates that
a common mechanism probably exists whereby endothelial
function is affected in disease states and is linked to oxidative
stress and the reduced bioavailability of NO (Katusic 2001).
However, a report from Nyström et al (2004) indicated that
BH4 infusion in a random crossover study in diabetic versus
nondiabetic patients improved insulin sensitivity, as assessed
by hyperinsulinemic isoglycemic clamp, but not endothelial
function, as assessed with brachial artery ultrasonography.
Ihlemann et al (2003) reported that BH4 corrects endothelial
dysfunction induced by an oral glucose challenge in healthy
subjects and that this was specific for the 6R and not the 6S
stereoisomer of BH4. Since both 6R and 6S are equally
effective as antioxidants but only 6R is effective as a cofactor
for eNOS, one can conclude that increasing the synthesis
of NO is likely to be more important than a simple
antioxidant action of BH4.
These data enforce the notion that nonspecific
antioxidant treatment may not prove effective in reducing
endothelial dysfunction and vascular disease (see Oxidative
stress, below). Data from animal studies have also been
illuminating as, for instance, Yang et al (2003) also used R
and S BH4, but in isolated aortae from spontaneously
hypertensive and control rats, and their data indicate that
superoxide generated from the autoxidation of BH4 enhances
endothelium-dependent contractions in tissues from the
hypertensive but not control animals. Thus, supplementation
with BH4 may also result in detrimental effects on vascular
functions resulting from the enhanced synthesis and/or
release of a putative endothelium-derived contracting
factor(s) (EDCF).
Overall we can conclude that cardiovascular function
will be compromised when the level of NO and/or
bioavailability is reduced. However, other endothelium-
derived factors may compensate for the loss of NO, and
one such endothelial cell-derived relaxing factor,
prostacyclin, can also be released via the activation of
G protein-coupled receptors and nonselective (stretch-
operated) cation channels on endothelial cells. Activation
of cyclooxygenase (COX), the synthesis of prostacyclin, and
activation of the prostacyclin receptor on vascular smooth
muscle cells increases cyclic adenosine monophosphate
levels and induces vasorelaxation.
Although it has been reported that COX-2 blockade does
not impair endothelium-dependent function in healthy
individuals (Verma et al 2001), changes in the ratio of COX-
derived vasodilator versus vasoconstrictor products, most
likely prostaglandin endoperoxides, may contribute to
endothelial-vascular dysfunction in cardiovascular disease
states including diabetes (Tesfamariam et al 1989, 1990;
Shimizu et al 1993; De Vriese et al 2000; Lagaud et al 2001;
Pannirselvam et al in press).
Role of endothelium-derived
hyperpolarizing factor
In many vessels, inhibition of endothelial NO and
prostacyclin synthesis does not completely inhibit
endothelium-dependent vasodilation. This NOS/COX-
insensitive relaxation has been linked to vascular smoothVascular Health and Risk Management 2005:1(1) 59
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muscle cell hyperpolarization, which has given rise to the
postulation of the “third mediator pathway” (that functions
in addition to the pathways regulated by NO and
prostacyclin) (McGuire et al 2001; Vanhoutte 2004). Rather
than a true chemical mediator, endothelium-derived
hyperpolarizing factor (EDHF) may reflect a purely
electrical coupling process between cells mediated by myo-
endothelial gap junctions that are made up of the connexion
proteins 37, 40, 43, and 45 (Griffith 2004; Sandow 2004).
Considerable heterogeneity has been reported with respect
to the pharmacological properties of EDHF, which has given
rise to the hypothesis that multiple EDHFs may exist (Ding
and Triggle 2001a; McGuire et al 2001; Triggle and Ding
2002). There are several putative candidates for EDHF:
potassium ions, epoxyeicotetranoic acid (often simply
abbreviated as EETs), and H2O2. H2O2 is discussed below
(see Oxidative stress). The EETs, which are products of CYP
enzymic metabolism of arachidonic acid, are attractive
candidates for EDHF because they hyperpolarize and relax
vascular smooth muscle cells by activating calcium-sensitive
potassium (KCa) channels. In situations of reduced NO
availability in eNOS knock-out mice there is an up-
regulation of EDHF-mediated relaxation in resistance
arteries (Waldron et al 1999; Ding et al 2000). If multiple
EDHFs exist, either as chemical mediators or as distinct
cell–cell (gap junctions) communication pathways, there is
the exciting prospect that novel therapeutic agents could, in
a vascular bed-dependent manner, be developed to
selectively modulate blood flow to a specific organ (Ding
and Triggle 2001b; Feletou and Vanhoutte 2004).
Conceivably, in disease states, the availability of EDHF (or
expression of gap junctions) may, like NO, be compromised.
Alternatively, EDHF may not simply act as a substitute for
NO, but may function in a pathophysiological manner and
have both short- and long-term detrimental effects on
vascular function. Regardless, a better understanding of the
cellular mechanisms that mediate EDHF may allow for the
therapeutic manipulation of this cell–cell communication
pathway (Ding and Triggle 2001b).
A number of studies have linked EETs to the EDHF
phenomenon and also to a protective role in cardiovascular
function. Provocatively, Fisslthaler et al (1999), on the basis
of their studies with native porcine coronary artery cells,
concluded that CYP 2C is an EDHF synthase. Krötz et al
(2004) demonstrated that EETs, in addition to
hyperpolarizing platelets, inhibited platelet P-selectin
expression in response to a procoagulation stimulus. Thum
and Borlak (2004) reported that oxidized LDL repressed
the synthesis of EETs in primary cultures of human coronary
arterial endothelial cells at the transcriptional level, possibly
via oxidized LDL, and enhanced ROS production and the
regulation of CYP genes by the transcription factor nuclear
factor 1 (NF-1). A polymorphism in the enzyme that
metabolizes the EETs, soluble epoxide hydrolase, has also
been associated with coronary artery calcification, and a
defect in this enzyme has been linked to the development
of atherosclerosis (Fornage et al 2004). Conversely,
inhibition of CYP 2C9 with sulfaphenazole has been shown
to improve endothelium-dependent vasodilation in patients
with CAD via, it is argued, the repression of ROS generation
in endothelial cells by CYP 2C9 (Fichtlscherer, Dimmeler,
et al 2004). Conceivably these data reflect that CYP 2C9
can (in a similar manner to that in which eNOS generates
both NO and ROS) generate both EETs and ROS and that
an imbalance in the generation of ROS exacerbates vascular
disease.
Thus, therapeutic advantages could result from increased
knowledge of the cellular basis of how the endothelium
modulates vascular tone and blood flow. The development
of novel therapeutic agents, as well as both diet and exercise
interventions, to enhance the bioavailability of NO as well
as enhance or inhibit the synthesis or action of EDHF-
mediated cell–cell communication pathways may have
benefits for the treatment of a variety of cardiovascular
diseases (Ding and Triggle 2001b; Feletou and Vanhoutte
2004).
Type 2 diabetes is frequently associated with obesity,
and of potential interest to the question of endothelial
dysfunction are a limited number of reports that describe
an adipocyte-derived vascular relaxing factor (ADRF) that
appears to be of periadventitial origin (Löhn et al 2002;
Dubrovska et al 2004; Fernández-Alfonso 2004; Verlohren
et al 2004). To date, the data available on ADRF are from
nondiabetic subjects and the nature of ADRF remains
unknown (other than that it is a hyperpolarizing factor)
(Dubrovska et al 2004). But what if adipocytes from
diabetics do not produce ADRF or the relaxing versus
contracting profile is changed and a contracting factor,
ADCF, is produced?
Biomarkers for cardiovascular
dysfunction
Although endothelial function can be readily assessed in
humans (Anderson 1999), it does require a level of technicalVascular Health and Risk Management 2005:1(1) 60
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sophistication that may not be readily available to all clinics,
and thus the question arises as to whether there is another
readily accessible surrogate marker for the health of the
endothelium.
Figure 1 provides an overview of some of the potential
pathways involved in linking several potential biomarkers
to endothelial dysfunction. Such a biomarker could provide
a very useful and, it is hoped, early indicator of vascular
disease and would provide important prognostic information
concerning the risk of future cardiovascular events (Suwaidi
et al 2000; Heitzer et al 2001). There is thus an urgent need
to identify non-invasive surrogate measurements of early
stage vascular disease in patients with diabetes; monitoring
the levels of such a biomarker(s) would be of obvious benefit
as a measure of the effectiveness of interventions. Indeed,
there has been considerable interest in identifying and
developing appropriate assays for both plasma biomarkers
(Ridker, Brown, et al 2004) for risk assessment of future
vascular events and genetic markers for predicting risk and
the progress of the disease (Gibbons et al 2004). Although
hyperlipidemia has long been used as a routine measure, it
is also apparent that the greater percentage of vascular events
occurs in individuals whose lipid profile is within the normal
range. Thus, given our increasing awareness that so-called
cholesterol-lowering drugs, such as the statins, have a
considerable repertoire of pleiotropic actions that involve
Figure 1 An elevation in plasma glucose brought on by the combined effects of diet, lifestyle, and genes leads to hyperglycemia. Hyperglycemia decreases endothelial
nitric oxide synthase (eNOS) activity and thus reduces the bioavailability of nitric oxide (NO) and also increases oxidative stress (enhanced production of •O2
–) via,
potentially, a multitude of pathways that may include the involvement of mitochondria, NADPH oxidase, xanthine oxidase, cytochrome P450, cyclooxygenase, and
lipoxygenase. Oxidative stress also further reduces the bioavailability of NO, thus reducing the inhibitory actions of NO on cytochrome P450 and other enzymes that
are involved in the elevation of •O2
–. Hyperglycemia may have direct or indirect effects to decrease the numbers and/or viability of endothelial progenitor cells (EPCs)
and thus reduce postnatal blood vessel repair and enhance the rate of endothelial cell senescence. Asymmetric dimethylmethylarginine (ADMA) is an endogenous
inhibitor of eNOS, and the metabolism of ADMA is decreased when oxidative stress is high and thus elevated ADMA will further decrease the bioavailability of NO.
Reduced availability of NO, elevated oxidative stress, and reduced levels of endogenous antioxidants add to the proinflammatory stimuli, and plasma and possibly
vascular levels of C-reactive protein (CRP) are elevated. CRP has been reported to decrease the stability of mRNA for eNOS, thus further reducing the synthesis of
NO. Endothelial dysfunction results from the reduction in the local production/bioavailability of NO and, possibly, changes in the contribution of endothelium-derived
hyperpolarizing factor (EDHF) to the regulation of vascular tone.
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direct actions on the vasculature, cholesterol levels may not
directly reflect the health of the vascular system (Liao and
Laufs 2004). Since the topics of biomarkers and genetic
markers for cardiovascular disease have been recently
reviewed, by Ridker, Brown, et al (2004) and Gibbons et al
(2004), respectively, we focus in the current review on the
appropriateness of two intensely studied biomarkers that
have been considered to be not only indicators of vascular
disease but, perhaps, also mediators of endothelial
dysfunction.
C-reactive protein
Studies of CRP have now gone full circle. It has been known
for almost 75 years that CRP is an acute-phase protein and
blood CRP rises from trace levels to high micrograms per
milliliter during inflammatory diseases (Tillett and Francis
1930; Gabay and Kushner 1999; Szalai and McCrory 2002).
The acute-phase response is a fundamental host defense
response, and CRP synthesis is rapidly elevated by the liver
as a result of an increase in interleukin (IL)-6 levels, with
serum concentrations of CRP rising from less than 1 µg/mL
to a thousand times higher within 48 hours of the
inflammatory stimulus (Gabay and Kushner 1999). It was
recognized as early as 1941 that CRP plays a potentially
important antimicrobial role by virtue of the ability of CRP
to bind to bacterial wall phosphocholine and precipitate the
collapse of the cell wall of Streptococcus pneumoniae
(Abernathy and Avery 1941). CRP has also been used as a
prognostic marker in several malignancies, and Wieland et
al (2003) concluded that CRP was a promising diagnostic
and prognostic index and follow-up monitor for both
pediatric and adolescent patients with Hodgkin’s disease.
Of particular interest is that Wieland et al (2003) reported
plasma CRP levels as high as 211 µg/mL in the plasma of
Hodgkin’s disease patients, far exceeding the levels reported
in patients with CAD. As discussed later in this review, Szalai
(2004) also presents compelling evidence that CRP may
play a protective role in autoimmune diseases and thus it
should not be surprising that plasma CRP levels are raised
in inflammatory diseases.
Considerable attention has been placed on CRP as a
powerful indicator of cardiovascular risk (Libby et al 2002;
Ridker et al 2002; Taubes 2002). Ridker et al (2002)
published the results of a large epidemiological study of
27 939 women and concluded that circulating CRP levels
were a better indicator of CAD than cholesterol. Similarly,
it was concluded that elevated levels of CRP and IL-6 predict
the development of type 2 diabetes and support a possible
role for inflammation in diabetogenesis (Pradhan et al 2001).
CRP is now accepted as a valuable prognostic marker –
blood levels are routinely measured – and by inference, has
come to be considered as an actual mediator/modulator,
rather than merely a corollary marker, of the inflammation
that contributes to CAD (Yeh 2004). These conclusions also
seem to have correlates in animal research, as studies with
the Israel sand gerbil (Psammomys obesus), an excellent
polygenic animal model of type 2 diabetes, provide a similar
correlation between acute-phase proteins (Tanis and serum
amyloid A protein), inflammation, and a mechanistic link
to type 2 diabetes and cardiovascular disease (Walder et al
2002). Furthermore, a mechanistic argument has been
presented that CRP mediates inhibitory actions on eNOS
and angiogenesis via a posttranscriptional effect on eNOS
mRNA stability (Verma et al 2002). CRP levels in patients
with CAD may also predict the bioavailability of NO
(Fichtlscherer, Breuer, et al 2004). Complexities in inter-
pretation of some of the clinical data, however, may relate
to the fact that CRP exists as both pentameric CRP and
monomeric CRP (mCRP) and risk may be greater for
patients with more of the mCRP (Khreiss et al 2004; Verma,
Szmitko, Yeh, et al 2004). Nonetheless, collectively these
reports provide both epidemiological and molecular support
for a direct role for CRP in diabetogenesis and endothelial
dysfunction. A CRP promoter polymorphism has also been
associated with type 2 diabetes in Pima Indians (Wolford et
al 2003). However, for reasons discussed below, we argue
that it is premature to conclude that such proteins are
mechanistically directly linked to the pathophysiology of
type 2 diabetes-related vascular diseases.
Should the above data that seem to strongly link plasma
levels of CRP to the incidence and severity of cardiovascular
disease be re-interpreted in terms of the long-established
primary function for CRP (and other acute-phase proteins)
as a host defense molecule? Certainly the results of another
large and very comprehensive study by Danesh, Wheeler,
et al (2004) challenge the utility of routine CRP
measurements as an indicator of CAD, questioning, in
particular, the magnitude of the association between CRP
and cardiovascular risk. These data have been the subject
of follow-up letters to the Editor of the New England Journal
of Medicine (Danesh, Pepys, et al 2004; Foody et al 2004;
Glynn and Cook 2004; Libby et al 2004; Ridker, Koenig, et
al 2004) and considerable debate. Should we reconsider the
use of CRP levels as an exact predictor of the severity of
CAD and possibly negate the contribution of CRP as a directVascular Health and Risk Management 2005:1(1) 62
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mediator of endothelial dysfunction and CAD? We need to
closely follow this debate before reaching a final conclusion.
Caution must also be applied to in vitro studies with human
recombinant CRP, as it has been reported that commercial
samples contain high levels of sodium azide, and the
activation of guanylyl cyclase by azide, as well as direct
toxic effects of azide, may explain at least some of the
reported in vitro effects of CRP (Van Den Berg et al 2004).
Studies with transgenic mice that express human CRP
have helped elucidate the biological functions of CRP in
humans. In the mouse, unique among mammals, CRP is
not an acute-phase protein and blood levels do not change
appreciably during inflammation, but rather this function is
served by mouse serum amyloid P protein. Ciliberto et al
(1987) generated CRP transgenic mice (CRPtg) that, with
an appropriate stimulus, express human CRP as an acute-
phase protein with blood levels comparable to those reported
for humans. Thus, CRPtg mice constitutively produce human
CRP such that serum levels are 10–20 µg/mL and in the range
seen in patients at high risk of CAD (Ridker et al 1997;
Szalai and McCrory 2002). Acute-phase levels of human
CRP in CRPtg mice also dramatically rise with an endotoxin
challenge (based on studies by Murphy et al 1995 that
indicate that a sequence downstream of the human CRP
coding sequence regulates induction by endotoxin), closely
resembling that seen in humans, and this increase in CRP
provides protection against bacterial infection (Szalai et al
1995, 2000; Szalai 2002). Studies by Szalai and colleagues
(Szalai and McCrory 2002; Szalai 2004) have been
interpreted to reflect a role for CRP in CRPtg mice to act as
an important host defense molecule. Szalai (2004) also
argues that CRP serves to bind autoantigens and protect
against autoimmunity as well as promote clearance of
apoptotic cells. In contrast, Hirschfield et al (2003) reported
that human CRP did not protect against lipopolysaccharide
challenge in CRPtg mice. This is perhaps not surprising,
since human CRP does not bind lipopolysaccharide and the
clinical data indicate that CRP levels remain in patients with
septic shock, suggesting that CRP is not protective, at least
in such extreme conditions. Danenberg et al (2003) reported
that arterial injury in CRPtg mice results in a faster rate of
arterial thrombosis than in control mice. Furthermore,
human CRPtg expression into the apolipoprotein knock-out
(ApoE–/–) mouse to produce the CRPtg
+/0/ApoE
–/– resulted
in significantly larger atherosclerotic lesions, but only at
29 weeks and not at 15 weeks (Paul et al 2004). The data
from Paul et al (2004) suggest that whereas CRP may
contribute to the chronic progression of the atherosclerotic
process, it may not be involved in the initiation of
atherosclerosis; however, data from the study by Danenberg
et al (2003) imply a role for CRP as an important causal
agent in acute cardiovascular events. Thus, quite differing
conclusions have been reached from studies of CRPtg mice,
and this may reflect the different contributions of CRP in
acute versus chronic pathophysiological states. Clearly
further studies must be pursued in this area.
Thus, as clearly stated by Goodman (2004), CRP is a
marker of inflammation, and serum levels will rise in almost
any condition when an individual is sick, reemphasizing
the long-standing contribution of Mark Pepys to our
knowledge of CRP. Since CRP is involved in host defense
mechanisms, should it also be considered as a contributor
to the pathophysiology and a specific marker for
cardiovascular disease? Perhaps the persistent increase in
liver-derived CRP, as seen in advanced cancer, AIDS, and
cardiovascular disease, is a key factor that contributes, in a
variable manner, to the development of endothelial
dysfunction. Further studies are justified concerning the
direct contribution of CRP to vascular pathophysiology, and
a point for consideration is the question: Does locally
produced (not of liver origin) CRP in the vasculature
contribute to the development of atherosclerosis (Yasojima
et al 2001)?
Asymmetric dimethylarginine
Asymmetric dimethylarginine (ADMA) is described in the
literature as an “endogenous inhibitor of NO synthase” and
as an “uber marker”, a biochemical factor that mediates the
adverse effects of a plethora of other risk factors and
biochemical markers (Böger 2003; Cooke 2004). Vallance
et al (1992a, 1992b) demonstrated that both N
w-
monomethyl-L-arginine (L-NMMA) and ADMA were
endogenous inhibitors of NOS, with ADMA being produced
in sufficient amounts that it could be considered to be a
potentially important endogenous modulator of eNOS
activity. Numerous studies provide data that seem to back
this pronouncement. The “normal” plasma levels of ADMA
have been reported to be 1.0 ± 0.1 µmol/L (Böger et al 1998).
Elevated plasma ADMA levels have been associated with
many cardiovascular risk factors including age, diabetes,
hyperlipidemias, hypertension, and insulin resistance (see
recent review by Cooke 2004). Plasma levels have been
reported ranging from 2.2 µmol/L in young hyper-
cholesterolemic, but otherwise healthy, individuals (Böger
et al 1997) to 2.5–3.5 µmol/L in elderly patients with
atherosclerosis and peripheral vascular disease (Böger et alVascular Health and Risk Management 2005:1(1) 63
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1998). The highest levels, however, are reported in renal
failure (Vallance et al 1992a; Kielstein et al 1999; Zoccali
et al 2001). ADMA is excreted in the urine either unchanged
or as the dimethylarginine dimethylaminohydrolase
(DDAH) metabolite and may rise as high as 8.7 ± 0.7 µmol/L
in end-stage renal failure (Vallance et al 1992a). The
calculated 50% inhibitory concentration (IC50) for ADMA
against NOS is 1.8 ± 0.1 µmol/L (Faraci et al 1995); it is
therefore not surprising that considerable attention has been
placed on ADMA as a diagnostic marker and as a mediator
of endothelial dysfunction. Interestingly, ADMA levels are
doubled and endothelium function decreased in diabetic
patients after a high-fat meal (Achan et al 2003), and
correlations have been made between insulin resistance and
ADMA levels (Stuhlinger et al 2002). Furthermore, LDL
has been shown to enhance ADMA synthesis in human
endothelial cells (Böger et al 2000).
Many of the above studies are, however, based on
correlations between plasma levels of ADMA and normal
versus disease states in patients. Although ADMA may prove
to be an appropriate “diagnostic marker” for vascular
disease, and there is a considerable data bank to back up
this assumption, it is unlikely that the pathophysiological
actions of ADMA are entirely mediated via the inhibition
of eNOS. This conclusion is reached by examining the data
and conclusions reported by Suda et al (2004) with eNOS
knock-out mice. The long-term treatment of mice with
ADMA induced coronary microvascular lesions to the same
extent in both wild-type and eNOS knock-out animals, and
the induction of these lesions was not prevented by the
administration of L-arginine. Furthermore, the treatment also
caused an up-regulation of vascular angiotensin-converting
enzyme and an increase in superoxide production to a
comparable extent in both strains. Finally, neither systemic
nor vascular NO production was attenuated by treatment
with ADMA. These data may reflect differences observed
when comparing acute with chronic effects of ADMA, as
the acute administration of ADMA in humans and animals
clearly leads to inhibition of endothelial NO synthesis
(Vallance et al 1992b), whereas the chronic effects of long-
term administration are not associated with reductions in
NO production (Suda et al 2004). Similar data have been
reported for short-term versus long-term administration of
the NOS inhibitor NG-nitro-L-arginine methyl ester (Bryant
et al 1995). These data indicate that the simple inhibition of
endothelial NO synthesis cannot be the primary mechanism
whereby the long-term vascular effect of ADMA leads to
endothelial dysfunction in vivo. The data also stress the value
of studies with knock-out mice for the elucidation of
pathophysiological mechanisms in humans. The data from
Suda et al (2004) indicate that ADMA enhances superoxide
production, via an angiotensin-I receptor-mediated process,
and also increases angiotensin-converting enzyme activity.
ADMA may therefore prove to be a good marker for
oxidative stress, as elevated oxidative stress inhibits
dimethylarginine dimethylaminohydrolase, the enzyme
responsible for degrading ADMA, and thus raises plasma
ADMA levels (Leiper et al 2002; Sydow and Munzel 2003).
In conclusion, since elevated oxidative stress is
associated with endothelial dysfunction, plasma ADMA
levels may prove to be a good indicator of the health of the
endothelium (Sydow and Munzel 2003), but there may not
be any direct correlation between chronic plasma levels of
ADMA and eNOS activity.
Additional measures of endothelial
dysfunction
If CRP and ADMA do not necessarily reflect a direct cause-
effect relationship to endothelial dysfunction (at least via
inhibition of eNOS), what other measures could also be
considered as potential biomarkers? Elevated oxidative
stress, although not specific for diabetes, would provide an
indication of the health of the endothelium and, in addition,
endothelial progenitor cells (EPCs) provide a measure of
the repair/regenerative capability of the cardiovascular
system.
Oxidative stress
Oxidative stress plays an important role in the pathogenesis
of cardiovascular disease, including atherosclerosis,
hypertension, and the macro- and microvascular diseases
associated with diabetes. Oxidative stress is defined as an
increase in ROS and/or a decrease in the antioxidant defense
mechanisms such as catalase, glutathione, superoxide
dismutase (SOD), thioredoxin, and selenoproteins, as well
as certain vitamins, notably vitamins C and E (Halliwell
1999; Halliwell and Whiteman 2004). It should also be noted
that the antioxidant roles of beta-carotene and ascorbic acid
have been questioned (Halliwell 1999).
We have recently reviewed the literature related to
oxidative stress and the endothelium and discussed the
nature of ROS and possible cellular sources (Ellis and
Triggle 2003). Touyz and Schiffrin (2004) have also recently
provided an excellent review of ROS in vascular biology,
and thus only a brief overview of this field follows.Vascular Health and Risk Management 2005:1(1) 64
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ROS are a family of molecules, including molecular
oxygen and its derivatives (•O2
–, •OH, and H2O2), which
are produced in all aerobic cells as a result of reduction-
oxidation (or redox processes) in cells. The free radical form
of NO, NO•, is also a “reactive oxygen species”. •O2
–, having
an unpaired electron, is quite unstable and short-lived;
however, although cell membranes are not permeable to •O2
–,
it can enter cells via anion channels. •O2
– is readily reduced
to H2O2, which (like NO•) can cross cell membranes, but
compared with •O2
– is not a free radical and is comparatively
stable; it is produced from the dismutation of •O2
– via a
SOD-mediated or spontaneous process and is scavenged by
catalase and glutathione peroxidase. Since the formation of
H2O2 is favored when •O2
– levels are low (or SOD high),
there has been speculation that H2O2 may have important
physiological functions that include a role as an EDHF in
humans and mice (Matoba and Shimokawa 2003), but see
Ellis et al (2003). •OH is the highly reactive reduction
product of H2O2 and is produced in the presence of ferric
ions (Fe2+) via the Fenton reaction. In situations where high
levels of •O2
– are produced and in the presence of NO, NO
is oxidized to produce the highly reactive and cytotoxic
peroxynitrite anion, ONOO
–. There is a considerable
literature that supports the argument that ONOO
–, as a
reactive nitrogen species and via the formation of
nitrotyrosine species, results in tissue damage that includes
the oxidation of eNOS and the subsequent dissociation of
dimeric eNOS into the inactive monomeric form, as well as
the inactivation of prostacyclin synthase (Zou et al 2004).
Alternatively, it has also been argued that the cytotoxicity
of ONOO
– has been overestimated and that it may simply
serve as an intermediate, by virtue of its rapid reaction with
antioxidants, in the use of NO to dispose of excess •O2
–, or
in the use of •O2
– to dispose of excess NO (Halliwell et al
1999).
Multifaceted sources of ROS in type 1 and type 2
diabetes include auto-oxidation of glucose, increased
substrate flux and decreased levels of NADPH through the
polyol pathway, formation of advanced glycation end
products and interaction with cellular targets, such as
endothelial cells, which may lead to oxidative stress and
oxidized LDL. Several enzymes are reported to be a source
of ROS, including xanthine oxidase (XO), NADH/NADPH
oxidase, COX, CYP, and uncoupled eNOS (Ellis and Triggle
2003; Pannirselvam et al 2003). Brownlee and colleagues
(Nishikawa, Edelstein, Brownlee 2000; Nishikawa,
Edelstein, Du, et al 2000) have argued that mitochondria
are the source of ROS and that uncoupling, for instance,
oxidative phosphorylation in endothelial cells that have been
treated with high glucose, prevents the sequelae of
hyperglycemia. Furthermore, NO is an important tonic
inhibitory factor for controlling mitochondrial respiration,
and thus a decrease in eNOS activity (or NO bioavailability)
will result in an increase in superoxide (•O2
–) production
by mitochondria. In particular, overproduction of •O2
– may
be detrimental because of its rapid interaction with NO,
which leads to the loss of NO bioavailability and a reduction
in the antiatherogenic effects of NO.
Elevated production of •O2
– may also be linked to plaque
instability (Cai and Harrison 2000; De Meyer et al 2003)
with the shoulder region of the plaque being a particularly
active area for •O2
– production (Sorescu et al 2002). Patients
with endothelial dysfunction, and in whom arterial
superoxide production is also elevated, are at highest risk
for vascular morbidity and mortality (Guzik et al 2000;
Heitzer et al 2001; reviewed by Channon and Guzik 2002).
The NAD(P)H oxidase family has been identified as a major
enzyme system involved in the generation of vascular
oxidative stress, and the molecular composition of vascular
NAD(P)H oxidases appears to vary in different cell types
(Paravicini et al 2002; Bengtsson et al 2003). The expression
of the membrane-bound cytochrome reductase domain
α-subunit, p22phox, and the larger flavin-containing
β-subunit called gp91phox has been reported to be elevated
in human sclerotic lesions (Azumi et al 1999; Sorescu et al
2002). It is likely that the molecular regulation of the
NAD(P)H oxidases within atherosclerotic plaques may be
highly relevant to plaque events, such as rupture. Further
investigations of the relevance of the NAD(P)H oxidases
versus other cellular sources of •O2
– to human vascular
disease pathogenesis are therefore justified and are required
particularly with respect to the contribution of other systemic
factors, such as oxidized LDL, angiotensin-II, and
proinflammatory cytokines, to atherosclerotic risk and the
progression of vascular disease in diabetes. However,
changes in the expression of •O2
–- producing enzymes may
prove to be an important predictor of the severity and
potential morbidity associated with vascular disease as well
as the enzymes serving as potential targets for corrective
interventions.
Hyperglycemia impairs endothelium-dependent
relaxation and this effect can be reversed with SOD, an
endogenous scavenger of superoxide anions (Tesferrariam
and Cohen 1992). Gene transfer of CuZn SOD and Mn SODVascular Health and Risk Management 2005:1(1) 65
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reduced both •O2
– production and endothelial dysfunction
in experimental diabetes, thus supporting the argument that
oxidative stress is an important target for the correction of
diabetes-related vascular disease (Zanetti et al 2001).
Clinical studies have also demonstrated that normal
endothelium function can be impaired by a 6-hour exposure
to high glucose (Williams et al 1998) and this impairment
can be prevented by vitamin C and vitamin E. Furthermore,
flow-mediated vasodilation is differentially affected by a
glucose load in normal versus impaired glucose tolerance
and type 2 diabetic patients (Kawano et al 1999).
Endothelium function in those with impaired glucose
tolerance and type 2 diabetes took considerably longer to
recover and was associated with a glucose load-induced
increase in oxidative stress (Kawano et al 1999). One can
speculate that endothelium function can be rapidly affected
by changes in blood glucose levels and that susceptibility
to long-term dysfunction may be determined as a result of a
failure of antioxidant protective mechanisms linked, at least
in part, to genetically determined susceptibility.
Hyperglycemia may competitively inhibit the transport
of ascorbic acid through facilitative glucose transporters,
thus promoting oxidative stress. There is also direct evidence
in humans that patients with type 2 diabetes have enhanced
oxidative stress as measured by lipid peroxidation (Pinkney
et al 1999). Unfortunately, clinical intervention studies with
antioxidants (notably vitamin C and/or E) have provided
confusing and conflicting data (Antoniades et al 2003), as
the interventions produced only variable reductions in
oxidative stress. Two large prospective intervention studies
with vitamin E and ramipril (the HOPE Study; Lonn et al
2002) and with vitamin C, vitamin E, and beta-carotene (the
MRC/BHF Heart Protection Study; Heart Protection Study
Collaborative Group 2002) reported no benefit for patients
with diabetes and cardiovascular disease. In both these
studies plasma concentrations of the vitamins as well as the
lipid profile were measured and reported but, surprisingly,
no measure was made of oxidative stress. Thus, in neither
study was it possible to conclude whether the interventions
were modifying oxidative stress in the patients – somewhat
akin, as noted by Halliwell (2000), to conducting a trial
with antihypertensive drugs but not monitoring blood
pressure. Although it can be argued that there is no clear
agreement as to which biomarkers best monitor oxidative
stress, the measurement of, for instance, the isoprostanes as
an indicator of lipid peroxidation would have provided one
reference set of data (Halliwell and Whiteman 2004). In
addition, the choice of the interventions may be questioned,
as vitamins C and E do not greatly affect isoprostane levels
(Levine et al 2001; Meagher et al 2001), although their
inclusion was probably based on their link to dietary sources.
In addition, it may well be that as yet undefined “co-
antioxidants” are essential and present in dietary sources of
vitamin E but missing in the supplements used in the studies
(Stocker 1999). It is also doubtful whether any of the
“classical antioxidants” are capable of preventing the
reaction of superoxide with NO, as this is one of the fastest
known biological reactions. Furthermore, concerns over the
measurement of ROS as well as the interpretation of
antioxidant intervention studies have been detailed by
Halliwell and Whiteman (2004) and Halliwell (1999, 2000a,
2000b).
As also noted by Kritharides and Stocker (2002), it is
important to determine and to then target the oxidative
processes that are operative within the artery wall. It is well
established that vitamin E (α-tocopherol) can inhibit the
oxidation of LDL in vitro, and each particle of LDL contains
between 6 and 10 molecules of α-tocopherol; however, via
the formation of α-tocopheroxyl, lipid peroxidation of LDL
can also be enhanced under certain conditions (Stocker
1999). Another consideration is that vitamin E is associated
with the lipophilic/hydrophobic domains of lipoproteins and
cell membranes and ROS are generated in the cytosolic and
extracellular compartments; it is conceivable that such
compartments are just far too separate. Touyz (2004) reached
similar conclusions in her review of why antioxidant
supplements have failed to benefit patients with elevated
blood pressure and, in addition, pointed out that many
patients would have been taking aspirin prophylactically,
and aspirin has antioxidant activity (Wu et al 2002). In
addition, non-oxidant actions of vitamin E may also be
important considerations in determining the effectiveness
of vitamin E use in clinical situations (Munteanu et al 2004).
Endothelial cell turnover and bone
marrow-derived endothelial progenitor
cells
The endothelial dysfunction that is commonly seen in
cardiovascular disease states may be linked to accelerated
endothelial cell death and reduced regeneration of
endothelial cells, as many of the changes reported in
endothelial cell function in cardiovascular disease are also
seen in senescent cells (Minamino et al 2004). EndothelialVascular Health and Risk Management 2005:1(1) 66
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cells normally turn over quite slowly, but nonetheless have
a finite lifetime. Thus, cardiovascular disease may induce
premature aging of the endothelium. Premature senescence
and a reduced ability of endothelial cells to be replaced by
progenitor cells may therefore be an important component
of the poor cardiovascular health of people with diabetes
(Minamino et al 2004; Voghel et al 2004). In the Zucker
diabetic rat, a model of insulin resistance and obesity,
Brodsky, Gealekman, et al (2004) reported that endothelial
cells undergo premature senescence in the vasculature, and
this senescence is associated with signs of vasculopathy.
Furthermore, endothelium-derived microparticles accelerate
endothelial dysfunction in cardiovascular disease states,
including diabetes (Tepper et al 2002; Brodsky, Zhang, et
al 2004). There are numerous descriptions of eukaryotic
cells shedding components of their plasma membrane
expressing the same antigenic determinants as the
corresponding cell surface and, in the case of endothelial
cells, such microparticles have been reported to have
procoagulant capability and express CD31, CD54, and
CD62E etc (Combes et al 1999; Brodsky, Zhang, et al 2004).
Voghel et al (2004) have explicitly stated that chronic
exposure to risk factors for cardiovascular disease leads to
telomere-associated premature senescence of the vascular
endothelium and may explain the early endothelial
dysfunction in patients with risk factors for cardiovascular
disease. The telomere, a cap at the end of each chromosome,
is very important for the chromosome replication process,
and with each replication cycle the telomere shortens. A
link between telomere shortening, cellular senescence
(Karlseder et al 2002) and human vascular disease has been
reported (Minamino and Komuro 2002). Acceleration of
telomere shortening, perhaps linked directly or indirectly
to endothelial dysfunction (ie, hyperglycemia and oxidative
stress), would also lead to the reduced viability of endothelial
progenitor cells (EPCs). EPCs are a subset of progenitor
cells that can be found in bone marrow and are important
for postnatal neovascularization and vascular repair, and thus
a decrease in the numbers and/or viability of EPCs would
exacerbate vascular disease (Hristov et al 2003a, 2003b).
Of relevance to this issue is our increasing awareness that
circulating endothelial cells (CECs) may reflect the
functional state of the endothelium. Koc et al (2003) recently
reported increased CECs in hemodialysis and hypertensive
patients and patients with diabetes. Their criterion for
identifying CECs was positive immunostaining with the
endothelial cell marker von Willebrand factor. Their study,
however, did not attempt to distinguish CECs from EPCs.
EPCs are usually identified by the expression of the stem
cell markers CD133, CD34, and vascular endothelial growth
factor receptor 2. As EPCs differentiate into endothelial cells
they lose CD133 and later CD34 expression and then start
to express von Willebrand factor as well as VE-cadherin
and, finally, eNOS (Hristov et al 2003a, 2003b). Asahara et
al (1997) first described the isolation of putative progenitor
CD34
+ cells with the use of magnetic microbeads from
human blood. Although the percentage of EPCs in the
peripheral blood is normally very low (0.002%), numbers
can be dramatically increased by, for instance, granulocyte
colony-stimulating factor.
Rauscher et al (2003) reported that the defective vascular
repair observed in the ApoE-deficient mouse is associated
with an age-dependent reduction of EPCs from these animals
thus suggesting an important role for EPC senescence in
the progression of vascular disease. Of interest too was the
ability of EPCs from young ApoE-deficient mice to suppress
plasma levels of the inflammatory cytokine IL-6 (Rauscher
et al 2003). Raised plasma IL-6 is reported to be reflective
of both aging and atherosclerosis and is argued to be also a
predictive marker for future CAD (Ferrucci et al 1999; Huber
et al 1999). The classification of IL-6 solely as an
inflammatory cytokine has been challenged (Carey and
Febbraio 2004), and indeed IL-6 may play an important
role as an exercise factor or myokine in humans (Pedersen
et al 2004). IL-6 is also involved in the stimulation of CRP
production by the liver (Gabay and Kushner 1999) and this,
again, raises the issue of whether CRP and IL-6 are “friends
or foes”. Quite possibly such distinctions may relate to both
the absolute level (ie, concentration) and the regulation of
plasma levels in acute versus chronic conditions.
In people with diabetes, EPCs demonstrate impaired
activity and these changes may contribute to the high
vascular morbidity that is inherent in diabetics (Tepper et al
2002). Little is known, however, about the processes that
regulate EPC numbers and function, but of importance for
people with diabetes is that exercise-induced myocardial
ischemia in patients with symptomatic CAD results in an
increase in circulating EPCs (Adams et al 2004). Additional
studies to explore how exercise, diet, and drug interventions
may interact and affect EPC numbers and function would
be of obvious interest.
Hyperglycemia, hyperglycemic memory,
and endothelial dysfunction
In type 1 diabetes it is not until at least 5 years after pancreas
transplantation that reversal of diabetic nephropathy lesionsVascular Health and Risk Management 2005:1(1) 67
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is observed (Fioretto et al 1998). Therefore, it has been
suggested that hyperglycemia induces phenotypic changes
in cells that persist despite a return to normoglycemia
(Fioretto et al 1998). Roy et al (1990) have also suggested
that hyperglycemia is responsible for the “induction of self-
perpetuating changes in gene expression”. The concept of
hyperglycemic memory (and the ability to reverse it) may
be an important factor in determining the success of
interventions directed towards improving vascular function
in diabetic patients. It is therefore worthy of speculation
that the premature senescence of endothelial cells linked to
a decreased potential for EPCs as contributors to endothelial
regeneration are key events in the deterioration of endothelial
function that is seen in diabetes and other vascular diseases.
It is clearly important to investigate the effects of diabetes
on endothelial cell senescence and the viability of EPCs
and whether controlling insulin sensitivity and blood glucose
levels with drug, diet, and/or exercise interventions affects
EPC levels and function. In this regard, Loomans et al (2004)
reported that EPCs from type 1 patients are dysfunctional
as illustrated in an in vitro angiogenesis assay and, despite
culturing these EPCs under normoglycemic conditions, such
functional differences between diabetes patients and controls
were maintained.
Concluding comments
Diabetes-associated vascular complications are a growing
concern worldwide, a major clinical problem, and there is
thus an urgent need to characterize appropriate diagnostic
markers that can provide an early prognostic indicator of
developing vascular disease. Endothelial dysfunction is an
early indicator of vascular disease and may directly or
indirectly be associated with increases in plasma ADMA,
CRP, IL-6, ROS, endothelial cell senescence, and decreases
in the numbers and viability of EPCs. Recent data from both
human and animal studies question a direct association
between an increase in plasma CRP and endothelial
dysfunction and also between ADMA and a reduction in
NO production, and further studies are needed to answer
the questions:
1. To what extent do CRP and ADMA serve as specific
biomarkers of vascular disease?
2. Is there a cause and effect relationship between CRP
and ADMA plasma/tissue levels in the development of
vascular disease?
Assays of the status of EPCs are likely to prove to be critical
for assessing the health of the vascular system, and
interventions that enhance EPC numbers and restore
angiogenic activity in diabetes may prove to be particularly
beneficial.
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Notes
1 We note that whereas acetylcholine (and in some clinical studies
methacholine) is employed it is unlikely that acetylcholine is
the physiological mediator of endothelial cell-dependent relaxation;
it is the most commonly used agent for probing endothelial
function/dysfunction.
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